Novartis announces MET inhibitor Tabrecta approved in Japan for advanced non-small cell lung cancer…
Novartis Pharma K.K. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14…
Read More...
Read More...
